| UHC Surest Medical and Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Surest Medical and Drug | Scenesse® (Afamelanotide) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Surest Medical and Drug | Spevigo® (Spesolimab-Sbzo) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Surest Medical and Drug | Viltepso® (Viltolarsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Surest Medical and Drug | Vyondys 53® (Golodirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| Medicare NCD | NCD 210.4.1 - Counseling to Prevent Tobacco Use | 2025-07-01 |
| Medicare NCD | NCD 190.11 - Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management | 2025-07-01 |
| Medicare NCD | NCD 20.9.1 - Ventricular Assist Devices | 2025-07-01 |
| Sunshine Health Clinical Policy | Diaphragmatic/Phrenic Nerve Stimulation | 2025-07-01 |
| Sunshine Health Clinical Policy | Intradiscal Steroid Injections for Pain Management | 2025-07-01 |